These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27094255)

  • 1. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
    Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
    Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
    Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
    Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
    Haybar H; Khodadi E; Shahjahani M; Saki N
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
    Basquiera AL; Soria NW; Ryser R; Salguero M; Moiraghi B; Sackmann F; Sturich AG; Borello A; Berretta A; Bonafé M; Barral JM; Palazzo ED; García JJ
    Hematology; 2009 Dec; 14(6):323-30. PubMed ID: 19941738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis.
    Ümit EG; Baysal M; Kırkızlar HO; Demir AM
    Turk J Haematol; 2024 Aug; 41(3):175-181. PubMed ID: 38801033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
    Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.